Type 2 diabetes is common, chronic and mostly managed with tablets, which makes it look like an obvious telehealth vertical. It is, but only for part of the pathway. Diagnosis and insulin initiation both sit outside what a remote-only service should attempt, and the operators who get this right build the platform around that boundary rather than around the medicine.
Why this is a management vertical, not a diagnosis one
Diagnosing type 2 diabetes relies on a laboratory-confirmed HbA1c result (or a fasting or random glucose test in specific circumstances), not a symptom checklist completed on a video call. Most patients arrive at diagnosis through primary care, where the test can be arranged and repeated if needed.
That makes the realistic telehealth model one of ongoing management for patients who already have a confirmed diagnosis, whether from the NHS or elsewhere, rather than a service that diagnoses from scratch. It is a similar shape to how a thyroid telehealth service works: the hard clinical gate sits at the front, and the ongoing titration and repeat prescribing sit behind it.
NICE NG28 and first-line treatment
NICE guideline NG28 sets out how type 2 diabetes should be managed in adults, alongside lifestyle and dietary advice. Metformin is typically the first-line medicine where drug treatment is needed, with individualised HbA1c targets rather than a single number applied to every patient.
Renal function matters from the outset, since metformin dosing and suitability depend on eGFR. A remote service needs a clear protocol for checking and re-checking kidney function before starting and at routine intervals afterwards, not just at the first prescription.
What suits a remote model: routine titration and repeat prescribing
Once a patient is stable on an established regimen, whether that is metformin alone or in combination with an SGLT2 inhibitor or a DPP-4 inhibitor, routine dose review, side-effect checks and repeat prescribing are genuinely well suited to a remote service with a structured review cadence.
GLP-1 receptor agonists sit in this vertical too, though usually prescribed for glycaemic control rather than weight management; where the same class overlaps with a weight-management service, the two indications need separate protocols rather than one blended pathway. Our GLP-1 weight management guide covers that overlap in more detail.
The clinical bottleneck in diabetes telehealth isn't the tablets, it's knowing where the platform's remit ends: diagnosis and insulin initiation both sit outside it.
Monitoring: what a remote service still needs to coordinate
- HbA1c review, typically every three to six months depending on stability and target, per NICE NG28 and the prescriber's own protocol
- Renal function and, where relevant to the medicine prescribed, liver function
- Blood pressure and lipid review, since cardiovascular risk sits alongside glycaemic control
- Annual foot check and retinal screening, most of which continues through the NHS Diabetic Eye Screening Programme rather than the telehealth platform itself
- A clear record of who is responsible for each check, so nothing falls into a gap between the remote service and the patient's GP
A private telehealth service does not need to replace every element of NHS diabetes review, but it does need to know which parts it owns and which parts it is relying on primary care to continue, and say so plainly to the patient.
Insulin, hypoglycaemia risk, and the referral line
Starting insulin is not a self-service remote decision. It typically needs structured education, hands-on titration support and closer monitoring than a repeat-prescribing platform is built to provide, and belongs with a specialist diabetes team rather than inside a telehealth onboarding flow.
Sulfonylureas carry a meaningful hypoglycaemia risk of their own and need the same caution. Where a patient is on a medicine that carries a hypoglycaemia risk, DVLA guidance on driving and diabetes becomes relevant, and a remote service should prompt patients toward that guidance rather than leaving it unaddressed. Prescriber discretion applies to every step of this pathway.
Diabetes telehealth rewards operators who build the referral line before they build the prescribing flow.
Building the service
The operational shape follows the clinical one: an intake pathway for patients with an existing, evidenced diagnosis, a structured HbA1c and renal-function review cadence, and a dispensing partner set up for routine repeat prescribing of metformin, SGLT2 inhibitors and similar agents rather than one-off acute supply.
Insulin initiation, suspected complications and anything outside stable routine management need an unambiguous referral pathway out of the platform, named explicitly in clinical SOPs rather than left to individual prescriber judgement. The same standard UK launch checklist applies underneath: superintendent pharmacist sign-off, CQC registration where the service requires it, and SOPs that state the red flags rather than imply them, an approach covered in our clinical SOPs guide.
How PExpo supports a diabetes launch
PExpo provides the regulated dispensing and operational layer underneath a diabetes management brand: same-day pharmacy fulfilment for repeat prescriptions, the compliance infrastructure a CQC-registered service needs, and integration support so a brand's review workflow connects cleanly to dispensing.
What we don't do is diagnose or set clinical protocol; that judgement sits with the brand's own prescribers and superintendent pharmacist, following NICE guidance and the monitoring boundaries set out above. Our role is getting the medicine to the patient reliably once that clinical decision has been made.
Type 2 diabetes is one of the steadier UK telehealth verticals when the platform respects where its remit ends: routine metformin and SGLT2 titration, structured HbA1c review and repeat prescribing suit a remote model well, while diagnosis and insulin initiation do not. See how PExpo's dispensing layer supports it on our brands page, or compare it with how other monitoring-led verticals are built on pricing.
Frequently asked questions
Can a UK telehealth service diagnose type 2 diabetes?
Not reliably as a remote-only service. Diagnosis relies on a laboratory-confirmed HbA1c result, usually obtained through primary care, rather than a symptom questionnaire. Most viable telehealth models work with patients who already have a confirmed diagnosis and focus on ongoing management.
Can insulin be started through a UK telehealth diabetes service?
Generally not as a self-service remote flow. Insulin initiation typically needs structured education and hands-on titration support best delivered by a specialist diabetes team, so most telehealth services treat it as a referral point out of the platform rather than something to prescribe directly.
How often is HbA1c monitored in remote diabetes management?
Typically every three to six months, depending on how stable the patient is and their individualised target under NICE NG28. The exact interval is a matter for the prescriber and the service's own clinical protocol, alongside routine renal function checks.
